Otsuka Medical Devices And Recor Medical Announce First FDA-Approved Renal Denervation System For Treatment Of Hypertension
Brief: Otsuka Holdings: Executive Director Makoto Inoue To Become Representative Director And COO, Effective Jan 1
Table: Otsuka Holdings -9-MTH group results (IFRS)
Brief: Otsuka Holdings - Otsuka Pharmaceutical Allies With Shapetx Of Us To Develop Novel Aav Gene Therapies For Ocular Diseases
Notice Regarding Transfer Of Sub-Subsidiary
US FDA panel votes against use of Medtronic's blood pressure treatment device (updated)
US FDA panel votes against use of Medtronic's blood pressure treatment device
US FDA panel backs Otsuka's blood pressure treatment device (updated)
US FDA panel backs Otsuka's blood pressure treatment device
US FDA staff raise no concerns about Otsuka, Medtronic blood pressure devices
Table: Otsuka Holdings -6-MTH group results (IFRS)
Sumitomo Pharma And Otsuka Announce Topline Results From Phase 3 Diamond1 And Diamond2 Clinical Studies Evaluating Ulotaront In Schizophrenia
2023 6-month group forecast(IFRS)
Table: Otsuka Holdings -Q1 group results (IFRS)
Japan's Otsuka Pharma gets FDA approval for Alzheimer's agitation drug (updated)
Brief: Lundbeck And Otsuka Announce U.S. FDA's Approval Of SNDA For Rexulti® (Brexpiprazole) For The Treatment Of Dementia Due To Alzheimer's Disease
Japan's Otsuka Pharma gets FDA approval for Alzheimer's agitation drug
Otsuka And Lundbeck Announce U.S. FDA Approval Of Supplemental New Drug Application For Rexulti® (Brexpiprazole) For The Treatment Of Agitation Associated With Dementia Due To Alzheimer’s Disease
Unit Completes Acquisition Of Otsuka Pharmaceutical India Private Limited